DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-75
SponsorBarcelonabeta Brain Research Center, Pasqual Maragall Foundation

About this trial

The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.

It will also examine how factors such as age, income, education, and health conditions may affect these levels.

In addition, the study will identify barriers that may make it difficult to use these blood tests in primary care.

The final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.

Eligibility criteria

Qualifiers

Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent

Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.

Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.

Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.

Disqualifiers

Cognitive decline defined by CDR>0.

Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life

Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study.

Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

250 Participants
are grouped into 5 trial groups

Sponsors and collaborators

Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

Lead sponsor

Universitat Pompeu Fabra

Collaborator

Hospital del Mar Research Institute (IMIM)

Collaborator

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Collaborator

Hospital del Mar

Collaborator